SALT LAKE CITY, Jan. 22 /PRNewswire-FirstCall/ -- World Heart Corporation ("WorldHeart") (Nasdaq: WHRT), a developer of mechanicalcirculatory systems, announced today that it has obtained commitments from institutional and individual investors to purchase approximately $7.3 million of its common stock in a private placement. WorldHeart has entered
Proceeds from the private placement are expected to be used for general corporate and working capital purposes.
The warrants will be exercisable at an exercise price equal to $4.90, which is the consolidated closing bid price of the common stock as reported on the Nasdaq Global Market on January 21, 2010. The warrants are immediately exercisable with half of the warrants expiring 15 months from the date of the issuance and remaining warrants expiring five years from the date of issuance.
In connection with the private placement, WorldHeart has agreed, subject to certain terms and conditions, to file a registration statement under the Securities Act covering the registration of the common stock and warrants acquired at closing within 60 days after the closing.
This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities. For additional information, please refer to WorldHeart 's current report on Form 8-K to be filed with the Securities and Exchange Commission with respect to the private placement.
WorldHeart is a developer of mechanical circulatory support systems based in Salt Lake City, Utah with additional facilities in Oakland, California, USA and Herkenbosch, The Netherlands. WorldHeart's registered office is in Delaware, USA.
Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements relating to the anticipated closing, and proposed use of proceeds, of the private placement, increase in shareholder value, access to investment capital, and the growth of WorldHeart's overall business, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: risks related to the satisfaction of the conditions to, and the timing of, the closing of the private placement, WorldHeart's need for additional capital in the future; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009, June 30, 2009 and September 30, 2009.
SOURCE World Heart Corporation
Subscribe to our Free Newsletters!
Snake antivenom is a medicine used for the treatment of patients suffering from snake envenomation.